ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bisphosphonates"

  • Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting

    Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study

    Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…
  • Abstract Number: 898 • 2015 ACR/ARHP Annual Meeting

    A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate

    PD Miller1, N Pannacciulli2, JP Brown3, E Czerwinski4, BS Nedergaard5, MA Bolognese6, J Malouf7, HG Bone8, JY Reginster9, A Singer10, C Wang2, RB Wagman2 and SR Cummings11, 1Colorado Center for Bone Research, Lakewood, CO, 2Amgen Inc., Thousand Oaks, CA, 3Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, 4Krakow Medical Center, Krakow, Poland, 5Center for Clinical and Basic Research, Aalborg, Denmark, 6The Bethesda Health Research Center, Bethesda, MD, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Michigan Bone and Mineral Clinic, Detroit, MI, 9University of Liège, Liège, Belgium, 10Georgetown University Medical Center, Washington, DC, 11San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA

    Background/Purpose: Oral bisphosphonates are the most common osteoporosis treatment, but inconvenient dosing regimens and side effects lead to low adherence. Less frequently dosed bisphosphonates, eg,…
  • Abstract Number: 1561 • 2015 ACR/ARHP Annual Meeting

    The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate

    Doo-Ho Lim1, Seokchan Hong2, Soo Min Ahn2, Byeongzu Ghang3, Wook Jang Seo4, Yong-Gil Kim1, Chang-Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 4Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

    Background/Purpose: Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast…
  • Abstract Number: 317 • 2015 ACR/ARHP Annual Meeting

    Relation of Incident Bisphosphonate Use to Trajectory of Joint-Space Width

    Tuhina Neogi1, Na Lu2, Jingbo Niu1, Jeffrey Duryea3 and Yuqing Zhang1, 1Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Radiology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Trials regarding bisphosphonate (Bisph) effects in knee osteoarthritis (OA) have been conflicting, and are unable to provide insights into long-term effects. While Bisph may…
  • Abstract Number: 350 • 2015 ACR/ARHP Annual Meeting

    Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study

    JungHee Koh1, Ji Hyeon Ju2, Min Kyung Chung3, Ji Hun Kim3, Seung Min Jung4, Ji Yeon Lee2, Jennifer Lee3, Seung-Ki Kwok5 and Sung-Hwan Park3, 1Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, 5[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than and those without RA, and are therefore exposed to Bisphosphonates (BPs) for longer.…
  • Abstract Number: 355 • 2015 ACR/ARHP Annual Meeting

    The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults

    Leyre Riancho-Zarrabeitia1, Maria T. García-Unzueta2, Jair A. Tenorio3, Juan Gómez-Gerique4, Víctor L Ruiz Pérez3, Karen E. Heath3, Pablo Lapunzina3 and José A. Riancho5, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 2Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 3Institute of Medical and Molecular Genetics. Hospital U. La Paz. IdiPAZ. Autonomous University of Madrid. CIBERER., Madrid, Spain, 4Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 5Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. University of Cantabria, Santander, Spain

    Background/Purpose: Different from infantile forms, adult forms of hypophosphatasia have less severe manifestations and may go unrecognized. Low serum levels of alkaline phosphatase (ALP), the…
  • Abstract Number: 368 • 2015 ACR/ARHP Annual Meeting

    The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital

    Masei Suda1, Masato Okada1, Yasuhiro Suyama2, Mitsumasa Kishimoto1 and Tokutaro Tsuda1, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Rheumatology, JR Tokyo General Hospital, Tokyo, Japan

    Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most clinically significant side effects of glucocorticoid use, and the prevention of GIOP has become more important…
  • Abstract Number: 2261 • 2014 ACR/ARHP Annual Meeting

    A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis

    Zsolt Kulcsar1, Lena Saleh2, Shravani Gangidi3 and Poonam Khadka4, 1Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, 2The Dartmouth Institute For Healthcare Policy and Clinical Practice, Lebanon, NH, 3The Dartmouth Institute For Healthcare Policy and Clinical Practice, lebanon, NH, 4Endocrinology, Dartmouth Hitchcock Medical Center, lebanon, NH

    Background/Purpose: Bisphosphonates are currently the drug of choice for treatment of osteoporosis. While anabolic agents like parathyroid hormone (PTH) have shown greater improvements in bone…
  • Abstract Number: 2263 • 2014 ACR/ARHP Annual Meeting

    Continued Zoledronic Acid Use in a Large Healthcare System

    Robert A. Overman1, Julie C. Lauffenburger2, Margaret L. Gourlay3 and Chad L. Deal4, 1Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, 2Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 3Family Medicine, University of North Carolina, Chapel Hill, NC, 4Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. With patients frequently having refill gaps greater than 30 days. Zoledronic…
  • Abstract Number: 2265 • 2014 ACR/ARHP Annual Meeting

    Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients

    Kowoon Joo1, Won Park2, Seong-Ryul Kwon3, Mie-Jin Lim3 and Kyong-Hee Jung3, 1Inha University Hospital, Incheon, South Korea, 2Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea

    Background/Purpose: Rheumatoid arthritis (RA) accelerates bone loss, increasing the risk of osteoporosis and osteoporotic fractures. We evaluated the effect of raloxifene and bisphosphonate on bone…
  • Abstract Number: 1162 • 2014 ACR/ARHP Annual Meeting

    Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population

    Mathilde Pioro1, Stephanie Ogorzaly2 and Maya Mattar3, 1Rheumatology, Cleveland Veterans Affairs Medical Center, Cleveland, OH, 2Pharmacy Service, Veterans' Affairs Medical Center, Cleveland Veterans' Affairs Medical Center, Cleveland, OH, 3Medicine/Rheumatology, University Hospitals Case Medical Center, Cleveland, OH

    Background/Purpose: Osteoporosis is a widely prevalent but underrecognized condition. Oral bisphosphonates are considered first-line treatment of osteoporosis in men and women however long term use…
  • Abstract Number: 854 • 2014 ACR/ARHP Annual Meeting

    Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial

    Chi Chiu Mok1, Angela Li2, Kar Li Chan1 and Ling Yin Ho1, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Radiology, Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose To compare the efficacy of golimumab(GLM) and pamidronate(PAM) in the treatment of SpA.Methods Inclusion criteria: (1) patients ≥18 years of age; (2) fulfills the…
  • Abstract Number: 831 • 2014 ACR/ARHP Annual Meeting

    Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)

    Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom

    Background/Purpose: Acute pseudogout is the most dramatic clinical manifestation of calcium pyrophosphate crystal deposition (CPPD). CPPD is most commonly sporadic and age-related but can rarely…
  • Abstract Number: 48 • 2014 ACR/ARHP Annual Meeting

    Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study

    Jonathan D. Adachi1, David Goltzman2, Ankita Modi3, Jackson Tang4, Chun-Po S. Fan4 and Jessica Weaver3, 1Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2McGill University, Montreal, QC, Canada, 3Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, 4Asclepius Analytics, New York, NY

    Background/Purpose Individuals with osteoporosis (OP) have an increased susceptibility to fractures. Prevention and treatment of postmenopausal OP is critical to decreasing the risk of non-traumatic…
  • Abstract Number: 1236 • 2013 ACR/ARHP Annual Meeting

    Outcomes and Costs Of Sacral Insufficiency Fractures

    Shahryar Hadavi1, Sanam Kia1, Christian Dejaco2, Bhaskar Dasgupta2 and Frances Borg3, 1Rheumatology Department, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 2Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 3Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom

    Background/Purpose: Sacral insufficiency fracture (SIF) is a poorly recognised cause of lower back pain in the elderly with significant potential morbidity. Diagnosis is often slow…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology